Rochester, NY, September 24, 2025 – After two decades of pioneering hematology and cancer stem cell research, Sanatela AT Medical Solutions Inc. proudly announces that the United States Patent and Trademark Office (USPTO) has officially issued its long-awaited patent for a revolutionary cancer detection and treatment platform. [Read more…]
Historic Patent Challenges to Pluripotent Stem Cells (ESCs and iPSCs)
The patent landscape for pluripotent stem cells, including embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs), is characterized by groundbreaking discoveries, legal challenges, and debates over accessibility. The patent environment surrounding these stem cell types is complicated, and there are a number of restrictions on how the cells can be used for commercial and strategic purposes. [Read more…]
30 Key Patents about Cord Blood (UPSTO)
A crucial benchmark to track for the cord blood market is the number and type of cord blood related patents that have been issued.
The United States Patent and Trademark Office (USPTO) has a patent analysis tool that offers a “Full Text and Image Database Search.” The database includes information about all American patents, from the first patent issued in 1790 to the most recent issue week.1 The text of patents issued from January 1976 to the present is fully searchable, including bibliographic data, such as the inventor’s name, the patent’s title, and the assignee’s name; the abstract; the full description of the invention; and the claims.2 [Read more…]
Cesca Therapeutics Granted Two Patents for Rapid Infusion of Autologous Bone Marrow Derived Stem Cells
Technology Fundamental to Cesca’s Proprietary SurgWerks™ Platform for CLI and AMI
RANCHO CORDOVA, Calif., Sept. 19, 2016 (GLOBE NEWSWIRE) — Cesca Therapeutics Inc. (NASDAQ:KOOL), an autologous cell-based regenerative medicine company, today announced that the United States Patent & Trademark Office (USPTO) has granted the Company the first two of a family of patent applications related to Cesca’s proprietary methods for the treatment of ischemic cardiovascular disorders, such as critical limb ischemia (CLI) and acute myocardial infarction (AMI). [Read more…]
Pluristem Fortifies IP Position and Partnering Potential in Japan with Two Key Cell Therapy Patents
In major news released today, Pluristem Therapeutics announced that it had been granted two key cell therapy patents in Japan. Pluristem Therapeutics is a clinical-stage biotechnology company that uses placental cells and a proprietary, three-dimensional technology platform to develop cell therapies for a broad range of diseases.
Therefore, the patents pertain to the three-dimensional growth of placental and fat cells and the use of placental cells grown with 3D technology:
- Patent No. 5733894, titled “Methods for Cell Expansion and Uses of Cells and Conditioned Media Produced Thereby for Therapy
- Patent No. 5766041, titled “Pharmaceutical Composition for Enhancing Subject Hematopoietic System”
To learn more about the company, see our recent interview Dr. Racheli Ofir, VP Research & Intellectual Property for Pluristem Therapeutics. Or, read the full press release below, printed with permission from Dr. Ofir. [Read more…]